Scratch That? De Novo Antibody Design Enters the AI Drug Discovery Toolbox

Abstract

Get full access to this article

View all access options for this article.

References

De novo design of epitope-specific antibodies against soluble and multipass membrane proteins with high specificity, developability, and function. Nabla Bio; 2024. Available from: https://nabla-public.s3.us-east-1.amazonaws.com/2024_Nabla_JAM_de_novo_antibodies.pdf [Last accessed: May 13, 25].

De novo design of hundreds of functional GPCR-targeting antibodies enabled by scaling test-time compute. Nabla Bio; 2025. Available from: https://nabla-public.s3.us-east-1.amazonaws.com/2025_nabla_de_novo_antibodies_gpcrs.pdf [Last accessed: May 13, 25].

Bennett

, Watson

, Ragotte

, et al. Atomically accurate de novo design of antibodies with RFdiffusion. bioRxiv, 2025; doi: 10.1101/2024.03.14.585103.

Trang

. Two biotechs say they’re using AI to conjure drugs from scratch. Their documents suggest otherwise. STAT; 2025. Available from: https://www.statnews.com/2025/02/10/ai-drug-development-claims-by-biotech-companies-absci-generate-biomedicines-questioned/ [Last accessed: May 13, 25].

Shanehsazzadeh

, McPartlon

, Kasun

, et al. Unlocking de novo antibody design with generative artificial intelligence. bioRxiv, 2024; doi: 10.1101/2023.01.08.523187

Absci First to Create and Validate De Novo Antibodies with Zero-Shot Generative AI. Absci; 2023. Available from: https://investors.absci.com/news-releases/news-release-details/absci-first-create-and-validate-de-novo-antibodies-zero-shot [Last accessed: May 13, 25].

Absci Highlights Progress and Updates Across Proprietary Pipeline and Leading AI Platform at 2024 R&D Day. Absci; 2024. Available from: https://investors.absci.com/news-releases/news-release-details/absci-highlights-progress-and-updates-across-proprietary [Last accessed: May 13, 25].

Marden

, Schmitt

, Zimmerman

, et al. Functional and structural characterization of a combination of pan-sarbecovirus antibodies with potent antiviral activity. bioRxiv, 2025; doi: 10.1101/2025.03.30.646023.

Ingraham

, Baranov

, Costello

, et al. Illuminating protein space with a programmable generative model. Nature, 2023; 623(7989):1070–1078; doi: 10.1038/s41586-023-06728-8

10.

Lin

. New Generative AI Model Designs Proteins Not Found in Nature. Genetic Engineering & Biotechnology News; 2023. Available from: https://www.genengnews.com/topics/artificial-intelligence/new-generative-ai-model-designs-proteins-not-found-in-nature/ [Last accessed: May 13, 25].

11.

Philippidis

. Genetic Engineering & Biotechnology News. Novartis, Generate:Biomedicines Sign Up-to-$1B AI Protein Drug Collaboration. 2024. Available from: https://www.genengnews.com/topics/artificial-intelligence/novartis-generatebiomedicines-sign-up-to-1b-ai-protein-drug-collaboration/ [Last accessed: May 13, 25].

12.

Shanker

, Bruun

TUJ

, Hie

, et al. Unsupervised evolution of protein and antibody complexes with a structure-informed language model. Science, 2024; 385(6704):46–53; doi: 10.1126/science.adk8946

13.

Jiang

, Yan

, Di Bernardo

, et al. Rapid in silico directed evolution by a protein language model with EVOLVEpro. Science, 2025; 387(6732):eadr6006; doi: 10.1126/science.adr6006

14.

Machine learning-guided generation of a potent combination of broadly neutralizing sarbecovirus antibodies with a high barrier to resistance. Generate Biomedicines; 2024. Available from: https://cdn.generatebiomedicines.com/team/IDWeek-2024_Preclinical-100924.pdf [Last accessed: May 13, 25].

15.

First-in-human study of a novel half life extended monoclonal antibody (GB-0669) against SARS-CoV-2 and related sarbecoviruses. Generate: Biomedicines; 2024. Available from: https://cdn.generatebiomedicines.com/team/IDWeek-2024-FTIH-presentation-100924.pdf [Last accessed: May 13, 25].